OTLK

Outlook Therapeutics, Inc. is a late-stage biopharmaceutical firm based in Cranbury, New Jersey, dedicated to advancing monoclonal antibody therapies specifically targeting ocular diseases. The company's innovative pipeline, focused on critical retinal conditions, addresses significant unmet medical needs in the ophthalmology sector, positioning it for potential regulatory approvals and market expansion. As Outlook Therapeutics moves closer to commercialization, it aims to significantly enhance patient care and clinical outcomes, leveraging its expertise to improve the quality of life for those affected by serious eye disorders.